Clinical Trial Update: Intravitreal Conbercept for Idiopathic Choroidal Neovascularization [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating intravitreal conbercept for idiopathic choroidal neovascularization (ICNV). The current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Choroidal Neovascularization

Drugs mentioned

• Conbercept (conbercept)

Snippet

Sponsor: Jiao Mingfei | Conditions: Idiopathic Choroidal Neovascularization | Phase 2 | Status: UNKNOWN